Compare RZLT & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RZLT | FLYX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 79.8M |
| IPO Year | N/A | N/A |
| Metric | RZLT | FLYX |
|---|---|---|
| Price | $1.84 | $3.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $12.33 | N/A |
| AVG Volume (30 Days) | ★ 12.5M | 15.0K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $362,955,000.00 |
| Revenue This Year | N/A | $28.47 |
| Revenue Next Year | N/A | $22.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.38 |
| 52 Week Low | $1.07 | $1.90 |
| 52 Week High | $11.46 | $6.90 |
| Indicator | RZLT | FLYX |
|---|---|---|
| Relative Strength Index (RSI) | 24.57 | 49.17 |
| Support Level | $1.07 | $3.08 |
| Resistance Level | $2.25 | $4.22 |
| Average True Range (ATR) | 0.60 | 0.38 |
| MACD | -0.77 | -0.02 |
| Stochastic Oscillator | 7.13 | 35.95 |
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.